Comments on: FDA Rejects Somaxon’s Application for Insomnia Drug http://www.xconomy.com/san-diego/2009/02/26/fda-rejects-somaxons-application-for-insomnia-drug/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 03:54:18 +0000 hourly 1 http://wordpress.org/?v=3.0.4 By: Effects insomnia | Insomnia Symptom http://www.xconomy.com/san-diego/2009/02/26/fda-rejects-somaxons-application-for-insomnia-drug/comment-page-1/#comment-48486 Effects insomnia | Insomnia Symptom Tue, 03 Mar 2009 00:02:31 +0000 http://www.xconomy.com/?p=14226#comment-48486 [...] If you're new here, you may want to subscribe to my RSS feed. Thanks for visiting!San Diego specialty drugmaker Somaxon Pharmaceuticals, (NASDAQ: SOMX said today the FDA turned down its application to market a new drug for insomnia. Somaxon says the FDA raised a number of issues related to the interpretation of the efficacy data … Read More About Insomnia [...] [...] If you’re new here, you may want to subscribe to my RSS feed. Thanks for visiting!San Diego specialty drugmaker Somaxon Pharmaceuticals, (NASDAQ: SOMX said today the FDA turned down its application to market a new drug for insomnia. Somaxon says the FDA raised a number of issues related to the interpretation of the efficacy data … Read More About Insomnia [...]

]]> By: We’ll Be Back on Sunday, and Breaking News for Friday | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Humor and Updates on the Latest Events in the Biotechnology and Pharmaceutical Industries http://www.xconomy.com/san-diego/2009/02/26/fda-rejects-somaxons-application-for-insomnia-drug/comment-page-1/#comment-47824 We’ll Be Back on Sunday, and Breaking News for Friday | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Humor and Updates on the Latest Events in the Biotechnology and Pharmaceutical Industries Fri, 27 Feb 2009 15:15:04 +0000 http://www.xconomy.com/?p=14226#comment-47824 [...] -Somaxon has struck out again as the FDA has rejected their NDA for doxepin (Silenor), claiming that the drug may increase the QT interval. This company was already in the graveyard, but now the coffin is in the ground. Somaxon’s stock was plummeting 82% from yesterday’s close of $2.14 down to $0.37. [Xconomy] [...] [...] -Somaxon has struck out again as the FDA has rejected their NDA for doxepin (Silenor), claiming that the drug may increase the QT interval. This company was already in the graveyard, but now the coffin is in the ground. Somaxon’s stock was plummeting 82% from yesterday’s close of $2.14 down to $0.37. [Xconomy] [...]

]]>